Pre-made Camrelizumab benchmark antibody ( Whole mAb, anti-PDCD1/PD-1 therapeutic antibody, Anti-CD279/PD1/SLEB2/hSLE1 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-090

Pre-Made Camrelizumab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Camrelizumab (SHR-1210) (INN) is an anti-PD-1 immune checkpoint inhibitor that is being investigated for hepatocellular carcinoma and Hodgkin lymphoma.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-090-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Camrelizumab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
INN Name Camrelizumab
TargetPDCD1/PD-1
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2016
Year Recommended2017
CompaniesChinese PLA General Hospital;Hangzhou Cancer Hospital;Incyte Corporation;Jiangsu Hengrui Medicine Co.;Nanjing Medical University;Peking University People's Hospital;Sun Yat-Sen University
Conditions ApprovedHodgkin's disease
Conditions ActiveNasopharyngeal cancer;Non-small cell lung cancer;Oesophageal cancer;Liver cancer;Biliary cancer;Cervical cancer;Cholangiocarcinoma;Colorectal cancer;Endometrial cancer;Fallopian tube cancer;Gastric cancer;Osteosarcoma;Ovarian cancer;Pancreatic cancer;Peritoneal cancer;Renal cell carcinoma;Solid tumours;Urogenital cancer;Diffuse large B cell lymphoma;Breast cancer;Malignant melanoma
Conditions Discontinuedna
Development Techna